TransCode Therapeutics In... (RNAZ)
NASDAQ: RNAZ
· Real-Time Price · USD
0.35
-0.07 (-17.16%)
At close: May 06, 2025, 3:59 PM
0.36
1.69%
After-hours: May 06, 2025, 05:46 PM EDT
-17.16% (1D)
| Bid | 0.35 |
| Market Cap | 8.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.79M |
| EPS (ttm) | -47.14 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.02 |
| Analyst | Buy |
| Ask | 0.36 |
| Volume | 2,096,911 |
| Avg. Volume (20D) | 9,244,173 |
| Open | 0.41 |
| Previous Close | 0.42 |
| Day's Range | 0.35 - 0.41 |
| 52-Week Range | 0.22 - 66.33 |
| Beta | 1.53 |
About RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 8, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol RNAZ
Analyst Forecast
According to 1 analyst ratings, the average rating for RNAZ stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 2724.86% from the latest price.
Stock ForecastsNext Earnings Release
TransCode Therapeutics Inc. is scheduled to release its earnings on May 16, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
-9.18%
TransCode Therapeutics shares are trading lower af...
Unlock content with
Pro Subscription
5 days ago
+38.71%
TransCode Therapeutics shares are trading higher after the company announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer.
